WuXi AppTec - B announced its mid-year report for 2024, showing that for the six months ended June 30, 2024, the company's revenue was RMB 868 million, which remained stable compared to RMB 877 million in the same period last year. The revenue mainly comes from the continuous commercialization of the company's CAR-T immune therapy product BeiNora®. The loss for the period was RMB 240.3 million, a decrease from RMB 380.4 million in the same period last year. Research and development expenses decreased from RMB 216.5 million in the same period last year to RMB 151.0 million, primarily due to improved operational efficiency and optimized R&D strategy. Sales expenses increased from RMB 60.2 million in the same period last year to RMB 76.2 million. As of the...Show More

WuXi AppTec - B announced its mid-year report for 2024, showing that for the six months ended June 30, 2024, the company's revenue was RMB 868 million, which remained stable compared to RMB 877 million in the same period last year. The revenue mainly comes from the continuous commercialization of the company's CAR-T immune therapy product BeiNora®. The loss for the period was RMB 240.3 million, a decrease from RMB 380.4 million in the same period last year. Research and development expenses decreased from RMB 216.5 million in the same period last year to RMB 151.0 million, primarily due to improved operational efficiency and optimized R&D strategy. Sales expenses increased from RMB 60.2 million in the same period last year to RMB 76.2 million. As of the end of the reporting period, the company's cash and cash equivalents were RMB 869.0 million. The company underwent various management changes during the reporting period, including the appointment of Mr. Liu Min as CEO and executive director, while Dr. Yiping James Li was reassigned from CEO to non-executive director. The company did not declare a mid-year dividend.